EUVIMEDEUVIMED entdecken
Open Access

Post-market surveillance for literature on QuantiFERON TB Gold Plus: what improvements can artificial intelligence bring?

J Reniewicz, R Alagna, L Kordylas, M Latacz, V Suryaprakash, U Nowak, A Kois-Ostrowska, J Weleszczuk, A Blacha, V Nikolayevskyy

IJTLD Open · 2026-05 · 3 (5) · 293-297

DOI: 10.5588/ijtldopen.25.0711 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IJTLD Open, online erschienen am 01.05.2026. Verfasst von J Reniewicz und 9 weiteren Autor:innen. Beteiligte Einrichtung: QIAGEN Wroclaw Sp. z o.o., Wroclaw, Poland. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Post-market surveillance (PMS) under the European Union In Vitro Diagnostic Regulation (IVDR) demands proactive, literature-based evidence, but mature assays like QuantiFERON TB Gold Plus (QFT-Plus) generate volumes of peer-reviewed and other literature that can strain manual workflows. METHODS We ran a comparative study of an AI-enabled literature-surveillance platform (jointly developed with Huma.ai called the Huma.ai Platform) versus manual search for QFT-Plus PMS. PubMed and PubMed Central were queried for publications in 2024; human studies published in English underwent duplicate screening and full-text appraisal. Outcomes were yield, precision, overlap/unique entries, and reviewer time. RESULTS The Huma.ai Platform retrieved 673 records, with 661 relevant to screening (98.21% precision). Manual searching retrieved 111, with 106 relevant to screening (95.50% precision): there were 103 shared and three manual-only items (metadata gaps). The Huma.ai Platform contributed 561 unique papers, 5 of which were excluded after full-text appraisal. In total, 664 articles were evaluated; no new safety signals were identified. Screening time averaged ∼16 s per article with Huma.ai Platform versus ∼60 s manually; full-text time (∼15 min per article) was similar. CONCLUSION AI-assisted surveillance substantially increases coverage and reduces screening effort while maintaining high precision. Thus it supports efficient, reproducible PMS for QFT-Plus.

Schlagwörter

Stichwörter der Autor:innen

diagnosisin vitro diagnostic medical deviceinterferon-gamma release assayliterature searchesnatural language processingtuberculosis

Autor:innen und Institutionen

  • QIAGEN Wroclaw Sp. z o.o., Wroclaw, Poland.
  • QIAGEN S.p.A., Milan, Italy.
  • QIAGEN Hilden GmbH, Hilden, Germany.
  • QIAGEN Manchester Ltd, Manchester, UK.
  • Imperial College London, London, UK.

Zitieren

APA

Reniewicz, J., Alagna, R., Kordylas, L., Latacz, M., Suryaprakash, V., Nowak, U., Kois-Ostrowska, A., Weleszczuk, J., Blacha, A., & Nikolayevskyy, V. (2026). Post-market surveillance for literature on QuantiFERON TB Gold Plus: what improvements can artificial intelligence bring?. IJTLD Open, 3(5), 293-297. https://doi.org/10.5588/ijtldopen.25.0711

Vancouver

Reniewicz J, Alagna R, Kordylas L, Latacz M, Suryaprakash V, Nowak U, et al. Post-market surveillance for literature on QuantiFERON TB Gold Plus: what improvements can artificial intelligence bring?. IJTLD Open. 2026;3(5):293-297. doi:10.5588/ijtldopen.25.0711

BibTeX
@article{Reniewicz2026,
  author = {Reniewicz, J and Alagna, R and Kordylas, L and Latacz, M and Suryaprakash, V and Nowak, U and Kois-Ostrowska, A and Weleszczuk, J and Blacha, A and Nikolayevskyy, V},
  title = {Post-market surveillance for literature on QuantiFERON TB Gold Plus: what improvements can artificial intelligence bring?},
  journal = {IJTLD Open},
  year = {2026},
  volume = {3},
  number = {5},
  pages = {293--297},
  doi = {10.5588/ijtldopen.25.0711}
}
Kostenlos starten →